Cited by 500Immune cells in cancerImmunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.

A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers

Open access

Kodumudi, Krithika N., Woan, Karrune, Gilvary, Danielle L., Sahakian, Eva, Wei, Sheng, Djeu, Julie Y.·2010·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-10-0733PMC PMC3874864

Open this paper in CoChat — free account

Abstract

Purpose: Myeloid-derived suppressor cells (MDSC) accumulate in tumor-bearing hosts and are associated with immune suppression. To date, there have only been few studies that evaluate the direct effect of chemotherapeutic agents on MDSCs. Agents that inhibit MDSCs may be useful in the treatment of patients with various cancers. Experimental Design: We investigated the in vivo effects of docetaxel on immune function in 4T1-Neu mammary tumor-bearing mice to examine if a favorable immunomodulatory effect accompanies tumor suppression. Primary focus was on the differentiation status of MDSCs and their ability to modulate T-cell responses. Results: Docetaxel administration significantly inhibited tumor growth in 4T1-Neu tumor-bearing mice and considerably decreased MDSC proportion in the spleen. The treatment also selectively increased CTL responses. Docetaxel-pretreated MDSCs cocultured with OT-II splenocytes in the presence of OVA323-339 showed OT-II–specific CD4 activation and expansion in vitro. In characterizing the phenotype of MDSCs for M1 (CCR7) and M2 [mannose receptor (CD206)] markers, MDSCs from untreated tumor bearers were primarily MR+ with few CCR7+ cells. Docetaxel treatment polarized MDSCs toward an M1-like phenotype, resulting in 40% of MDSCs expressing CCR7 in vivo and in vitro, and macrophage differentiation markers such as MHC class II, CD11c, and CD86 were upregulated. Interestingly, docetaxel induced cell death selectively in MR+ MDSCs while sparing the M1-like phenotype. Finally, inhibition of signal transducer and activator of transcription 3 may in part be responsible for the observed results. Conclusions: These findings suggest potential clinical benefit for the addition of docetaxel to current immunotherapeutic protocols. Clin Cancer Res; 16(18); 4583–94. ©2010 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-10-0733

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
M-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287
Taxol stabilizes microtubules in mouse fibroblast cells.
Schiff, P. B., & Horwitz, S. B. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1561 · Cited by 1,971
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J., Nagaraj, S., Collazo, M. M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,340
Altered macrophage differentiation and immune dysfunction in tumor development
Sica, A., & Bronte, V. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31422 · Cited by 1,258
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E. S., Cole, D. J., & Montero, A. J. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,217
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity
Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0883 · Cited by 1,054

Show all 42 references

Sorted by citations

Items 401–499 of 499

CD15 + tumor infiltrating granulocytic cells can predict recurrence and their depletion is accompanied by good responses to S‐1 with oral cancer
Seki, M., Sano, T., Ogawa, M., Yokoo, S., & Oyama, T. (2021) · Head & Neck · doi:10.1002/hed.26712 · Cited by 6
Dual identity of tumor-associated macrophage in regulated cell death and oncotherapy
Shao, Y., Wang, Y., Su, R., Pu, W., Chen, S., Fu, L., Yu, H., & Qiu, Y. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17582 · Cited by 6
Immune Checkpoint Inhibitors in Lung Cancer – An Unheralded Opportunity?
Marshall, R., Popple, A. L., Kordbacheh, T., Honeychurch, J., Finn, C. F., & Illidge, T. (2017) · Clinical Oncology · doi:10.1016/j.clon.2016.12.003 · Cited by 6
Establishment of Synergistic Chemoimmunotherapy for Head and Neck Cancer Using Peritumoral Immature Dendritic Cell Injections and Low-Dose Chemotherapies
Ishii, H., Chikamatsu, K., Igarashi, S., Takahashi, H., Sakamoto, K., Higuchi, H., Tanaka, S., Matsuoka, T., & Masuyama, K. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.11.006 · Cited by 6
Future therapeutic strategies for metastatic prostate cancer
Smits, M., Gerritsen, W. R., & Mehra, N. (2019) · Tijdschrift voor Urologie · doi:10.1007/s13629-019-00261-y · Cited by 6
Robust and durable response to first-line treatment of pembrolizumab combined with chemotherapy in two patients with metastatic thymic squamous cell carcinoma: Case report
Chen, C., Sun, P., & Long, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.941092 · Cited by 6
Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacy
Gbadamosi, M. O., Molchan, E., Makarem, M. S., Coleman, K. L., Ohaegbulam, A., & Streeks, K. H. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2527303 · Cited by 6
Selecting immuno-oncology–based drug combinations – what should we be considering?
Festino, L., Vanella, V., Trojaniello, C., & Ascierto, P. A. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1518713 · Cited by 6
Long-Lasting Complete Remission in a Patient With Metastatic Metaplastic Breast Cancer Treated With Immune Checkpoint Inhibitor and Chemotherapy: A Case Report and a Review of the Literature
Al-Awadhi, A. M., Alnaqbi, S., & Albawardi, A. S. (2024) · Cureus · doi:10.7759/cureus.53419 · Cited by 5
Tumor-induced Myeloid-derived Suppressor Cells
Ostrand‐Rosenberg, S., Sinha, P., Beury, D. W., Chornoguz, O., & Parker, K. H. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394296-8.00028-2 · Cited by 5
Survival Benefit from RectroNectin-Activated Cytokine-Induced Killer Cells Combined with Chemotherapy in Advanced EGFR Wild-Type Lung Adenocarcinoma
Zhao, L., Li, W., Wang, Z., Yang, Y., Zhang, Y., Shang, Y., Ren, X., & Gao, Q. (2018) · Immunotherapy · doi:10.2217/imt-2017-0140 · Cited by 5
Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies
Kozai, H., Ogino, H., Mitsuhashi, A., Nguyen, N. T., Tsukazaki, Y., Yabuki, Y., Ozaki, R., Yoneda, H., Sato, S., Hanibuchi, M., et al. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15200 · Cited by 5
Chemotactic signaling pathways in prostate cancer: Implications in the tumor microenvironment and as potential therapeutic targets
Bujanda, Z. A. L., Hadavi, S. H., de Porras, V. R., Martinez‐Balibrea, E., & Dallos, M. C. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.03.008 · Cited by 5
Decoding the influence of the immune system and immunotherapy targets on carcinomas: A hidden prism in oral cancer therapy
Dhara, V., Shetty, S. S., de Arruda, J. A. A., Silva, T. A., Russo, R. C., Shetty, N. J., Pidaparthi, M., Wollenberg, B., Rao, V. U. S., & Gopinath, T. P. S. (2022) · Disease-a-Month · doi:10.1016/j.disamonth.2022.101353 · Cited by 5
Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial
Opdam, M., van Rossum, A. G. J., Hoogstraat, M., Bounova, G., Horlings, H. M., van Werkhoven, E. D., Mandjes, I. A. M., van Leeuwen‐Stok, A. E., Canisius, S., van Tinteren, H., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110425 · Cited by 4
The effects of docosahexaenoic acid (DHA) on plasma cytokines, oxylipins, and tumor-infiltrating lymphocytes from women with breast cancer undergoing neoadjuvant chemotherapy in the DHA-WIN trial
Munhoz, J., Bigras, G., Newell, M., Rivas‐Serna, I. M., Mazurak, V. C., Goruk, S., Joy, A. A., Ghosh, S., Courneya, K. S., Hemmings, D. G., et al. (2025) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2025.110025 · Cited by 5
Advances in nanomedicine strategies for modulating the tumor microenvironment: Recent progress and clinical perspectives
Emran, T. B., Amin, M. A., Rab, S. O., Jahnavi, P., Vodeti, R., Gupta, J. K., Arjun, U. V. N. V., Umamaheswari, T. N., Balaji, P., Dayalan, G., et al. (2025) · 3 Biotech · doi:10.1007/s13205-025-04651-5 · Cited by 5
Plasmodium yoelii Infection Enhances the Expansion of Myeloid-Derived Suppressor Cells via JAK/STAT3 Pathway
Zhu, Y., Zhou, L., Mo, L., Hong, C., Pan, L., Lin, J., Qi, Y., Tan, S., Qian, M., Hu, T., et al. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300541 · Cited by 4
Cytostatic cancer therapy modulates monocyte-macrophage cell functions: how it impacts on treatment outcomes
Patysheva, M. R., Stakheyeva, M. N., Larionova, I., Fedorov, A. A., Kzhyshkowska, J. G., & Чердынцева, Н. В. (2019) · Experimental Oncology · doi:10.32471/exp-oncology.2312-8852.vol-41-no-3.13597 · Cited by 4
Role of myeloid cells in the tumor microenvironment
Balakrishnan, A., Vig, M., & Dubey, S. (2022) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.33 · Cited by 4
[Metronomic Chemotherapy--A New Path to Treat Advanced Non-small Cell Lung Cancer].
Zhang, S., Liu, J., & Cheng, Y. (2015) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2015.04.08 · Cited by 4
Immune Stimulatory Features of Classical Chemotherapy
der Most, R. G. V., Nowak, A. K., & Lake, R. (2007) · Elsevier eBooks · doi:10.1016/b978-012372551-6/50077-8 · Cited by 4
CCR 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxel—How Far Science Has Come
Bashour, S. I., & Ibrahim, N. K. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2554 · Cited by 4
Immune Suppressive Myeloid-Derived Suppressor Cells in Cancer
Ostrand‐Rosenberg, S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.17015-8 · Cited by 4
Promising Nanotechnology-Based Strategies for Melanoma Treatment
Sias-Fonseca, L., Costa, P. C., Saraiva, L., Alves, A. C., & Amaral, M. H. (2025) · Colloids and Interfaces · doi:10.3390/colloids9040053 · Cited by 3
Docetaxel-Aggravated Psoriasis
Yang, S., Kim, B. R., Choi, C. W., & Youn, S. W. (2019) · Annals of Dermatology · doi:10.5021/ad.2019.31.2.240 · Cited by 3
Tumor immunology
Sharif, P. M., Khoshbin, A. P., Nasrollahzadeh, E., Keshavarz‐Fathi, M., & Rezaei, N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818006-8.00003-7 · Cited by 3
CD4+T cells suppress immune response to cancer: novel targets for antitumor efforts
Nelson, A., Nair, S., & Nagaraj, S. (2012) · Expert Review of Clinical Immunology · doi:10.1586/eci.12.29 · Cited by 3
Cancer Progression Related with Tumor-associated Macrophages
Ethiraj, P., Loganathan, T., & Arul, S. (2016) · Cancer and Oncology Research · doi:10.13189/cor.2016.040401 · Cited by 3
Tumor-Induced Myeloid-Derived Suppressor Cells
Sanctis, F. D., Bronte, V., & Ugel, S. (2017) · ASM Press eBooks · doi:10.1128/9781555819194.ch49 · Cited by 3
Role of myeloid-derived suppressor cells in bladder cancer and targeted therapeutic strategies
Boillat, S., Goasmat, V., Derré, L., & Domingos‐Pereira, S. (2025) · Gene · doi:10.1016/j.gene.2025.149772 · Cited by 2
Improvement in telangiectatic rosacea as a side-effect of monthly docetaxel therapy
Tokunaga, M., Endo, Y., Fujisawa, A., Tanioka, M., Nomura, T., & Miyachi, Y. (2013) · Clinical and Experimental Dermatology · doi:10.1111/ced.12180 · Cited by 2
Cancer Immunotherapy
Guth, A., & DOW, S. W. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2362-5.00013-x · Cited by 3
Peptide-based vaccines
Hamilton, D. H., Schlom, J., & Jochéms, C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823901-8.00008-x · Cited by 2
Immune Stimulatory Features of Classical Chemotherapy
Lesterhuis, W. J., Nowak, A. K., & Lake, R. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394296-8.00024-5 · Cited by 2
Effect of crosstalk among conspirators in tumor microenvironment on niche metastasis of gastric cancer.
Zhu, Z., Shi, L., Dong, Y., Zhang, Y., Yang, F., Wei, J., Huo, M., Li, P., & Liu, X. (2022) · PubMed Central · Cited by 2
Lipid peroxidation and superoxide dismutase activity in pea seedlings under clinorotation.
Бараненко, В. В. (1998) · PubMed · Cited by 2
Dynamic Profiling of the Immune Tumor Microenvironment in Locally Advanced Gastric Cancer Treated with Perioperative Chemotherapy
Pecora, I., Ugolini, C., Giannini, R., Giordano, M., Vivaldi, C., Lencioni, M., Santi, S., Massa, V., Pallabazzer, G., Catanese, S., et al. (2023) · Oncology · doi:10.1159/000530853 · Cited by 1
Adoptive immunotherapy with cells from tumor-draining lymph nodes activated and expanded in vitro
Haynes, C., Graham, L., & Bear, H. D. (2023) · Methods in cell biology · doi:10.1016/bs.mcb.2023.04.002 · Cited by 1
Drug Delivery Systems Repurposing Taxanes as Antitumor Immune Modulators
Choi, S., Chi, S., Han, C. Y., Cho, K. J., Son, S., Thomas, S. N., & Kim, J. (2026) · Biomaterials Research · doi:10.34133/bmr.0390 · Cited by 1
Myeloid derived suppressor cells in neuroblastoma: mechanisms of immune evasion and therapeutic opportunities
Choo, H. S., Yu, T., Pham, T., Singh, N., & Joshi, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1773622 · Cited by 1
The Landmark Series: Neoadjuvant Therapy for Patients with Resectable Gastroesophageal Junction Adenocarcinomas
Pettigrew, M. F., Coburn, N. G., Woo, Y., & Porembka, M. R. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-20114-4 · Cited by 1
Cancer Immune Modulation and Immunosuppressive Cells: Current and Future Therapeutic Approaches
Sasso, M. S., Bronte, V., & Marigo, I. (2014) · Advances in delivery science and technology · doi:10.1007/978-3-319-08084-0_7 · Cited by 1
Strategies to Target Tumor Immunosuppression
Draghiciu, O., Nijman, H. W., & Daemen, T. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_5 · Cited by 1
Metronomic Chemotherapy Regimens Using Microtubule-Targeting Agents: Mechanisms of Action, Preclinical Activity and Future Developments
Pasquier, E., Kavallaris, M., & André, N. (2014) · Springer eBooks · doi:10.1007/978-3-662-43604-2_5 · Cited by 1
Effect of Pharmaceutical Compounds on Myeloid-Derived Suppressor Cells
Bruchard, M., & Ghiringhelli, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_11 · Cited by 1
[Research progress on nonspecific immune microenvironment in breast cancer].
Xu, Z., Cui, Y., Li, Y., & Guo, Y. (2018) · PubMed Central · doi:10.3785/j.issn.1008-9292.2018.08.16 · Cited by 1
Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) plus platinum‐etoposide versus platinum‐etoposide alone for first‐line treatment of extensive small cell lung cancer
Gao, Y., Shi, S., Liu, M., Wu, F., Zhang, J., Song, F., & Tian, J. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014809 · Cited by 1
Understanding Macrophage-Associated Diseases and Applications of Nanodrug Delivery Systems
Bigoniya, P. (2022) · Springer eBooks · doi:10.1007/978-3-030-84164-5_5 · Cited by 1
Effects of Metronomic Chemotherapy on Immunity
Harada, M. (2014) · Springer eBooks · doi:10.1007/978-3-662-43604-2_3 · Cited by 1
The Role of Myeloid Derived Suppressor Cells in Cancer
Weiss, J. M. (2013) · Springer eBooks · doi:10.1007/978-94-007-6217-6_16 · Cited by 1
Immunogenic Chemotherapy Using Cyclophosphamide and Gemcitabine
Harada, M. (2016) · Immunotherapy Open Access · doi:10.4172/2471-9552.1000124 · Cited by 1
Immunotherapy and Targeted Therapies in Advanced Castration Resistant Prostate Cancer
Joaquim Bellmunt, B., & Moreno, I. (2017) · Springer eBooks · doi:10.1007/978-3-319-42769-0_24 · Cited by 1
Targeted delivery and reprogramming of myeloid-derived suppressor cells (MDSCs) in cancer
Katoh, H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85781-9.00015-4 · Cited by 1
Cancer Immunotherapy
DOW, S. W., & Guth, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-59496-7.00014-1 · Cited by 1
Programming of MDSC: New Opportunities for Targeted Therapy
Svider, P. F., Chen, S., Sikora, A. G., & Yang, W. (2013) · Springer eBooks · doi:10.1007/978-94-007-6217-6_24
Immuntherapie von Tumoren mit den Pattern-Recognition-Rezeptor-Liganden CpG und poly(I:C) hemmt die Funktion myeloischer Suppressorzellen
Bittner, P. M. (2012) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.15229
Immunotherapy and cancer – making the past prologue
Slovin, S. F. (2012) · Clinical Investigation · doi:10.4155/cli.12.82
Therapeutic potential of monocytic MDSCs from peripheral blood monocytes in transplant rejection
(2016) · Macrophage · doi:10.14800/macrophage.1069
Microenvironmental Control of Metastatic Progression
Roskelley, C. D. (2014) · Cancer metastasis · doi:10.1007/978-3-319-12136-9_6
Lung Cancer Immunotherapy: Programmatic Development, Progress, and Perspectives
Hirschowitz, E. A., Foody, T., & Yannelli, J. R. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1419-3_23
Factors Affecting Cancer Behavior with Special Reference to Lymphatic Vessels, Macrophages, EGFR, and Pim-1 in Colorectal Cancer
Ålgars, A. (2012) · UTUPub (University of Turku)
Immunosuppressive myeloid cells under normal and neoplastic conditions
Hamilton, M. J. (2011) · cIRcle (University of British Columbia) · doi:10.14288/1.0072452
Recent Advances in Cancer Immunotherapy
Chikamatsu, K., & Masuyama, K. (2012) · Practica Oto-Rhino-Laryngologica · doi:10.5631/jibirin.105.87
Immunomodulation of myeloid-derived suppressor cells by particulate b-glucan in cancer.
Albeituni, S. (2015) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/2332
Der Effekt einer durch Toll-like-Rezeptor-Liganden induzierten Interferon--Produktion auf myeloide Suppressorzellen
Tumorimmunologie, A., & Bourquin, C. (2014)
Controversies in Neoplastic Myeloplasia
Talmadge, J. E. (2016) · SpringerBriefs in immunology · doi:10.1007/978-3-319-26821-7_1
Efficacy of multiple anticancer therapies may depend on host immune response
Karri, K., & Bastola, D. R. (2017) · Advances in Science Technology and Engineering Systems Journal · doi:10.25046/aj020398
Ontogeny of intestinal intratumoural macrophages and their contribution in cancer regulation
Soncin, I. (2018) · doi:10.32657/10220/46940
担癌状態における骨髄由来抑制細胞（Myeloid derived suppressor cells）の治療による変化
智子, 田., 公大, 山., 大坪, 大., 有本聡, 将康, 西., 寛, 長., 将士, 山., 新悟, 金., 佳子, 松., 太郎, 押., et al. (2016) · doi:10.18947/cytometryresearch.26.2_27
Development of Antitumor Cellular Immunity
Welters, M. J. P., & van der Burg, S. H. (2013) · Springer eBooks · doi:10.1007/978-94-007-6217-6_5
Cancer Vaccines
Giese, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-25832-4_12
Strategies to Target Tumor Immunosuppression
Koutsoumpli, G., Draghiciu, O., Nijman, H. W., Oyarce, C., & Daemen, T. (2020) · Springer eBooks · doi:10.1007/978-3-030-50287-4_5
Introduction to Anatomy and Physiology of Macrophages from Drug Delivery Perspective
Duong, T. B., & Ho, L. (2022) · Springer eBooks · doi:10.1007/978-3-030-84164-5_2
Wings Outstretched: New Contributions in Undergraduate Research
(2017) · PSU McNair Scholars Online Journal · doi:10.15760/mcnair.2017.01
Combination Therapy
Keshavarz‐Fathi, M., & Rezaei, N. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814039-0.00013-8
In-vitro- und In-vivo-Untersuchungen zum Gemcitabinmetabolismus von Makrophagen im Duktalen Adenokarzinom des Pankreas
Buchholz, S. M. (2022) · doi:10.53846/goediss-9454
Strategies to overcome interleukin-1-mediated immune suppression and resistance to immunotherapy in cancer
Puthenveetil, A., Dubey, S., & Garg, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824273-5.00004-0
Development of a Myeloid-Derived Suppressor Cells-Related Genes Predictive Signature for Prognostic Survival and Immunotherapeutic Responses in Hepatocellular CarcinomaPreprint
Zhao, M., Li, C., & Gong, J. (2023) · Research Square · doi:10.21203/rs.3.rs-3712616/v1
A Case of New-onset Psoriasis During Docetaxel Treatment
Kim, H.-N., Woo, B., Kim, Y. C., Kim, K. E., Jeon, J. H., & Baek, Y. S. (2023) · Daehan geonseon hakoeji (Online) · doi:10.23203/psoriasis.2023.20.2.79
Chemoimmunotherapy Combination for Solid Tumors
Yan, Y. (2024) · Springer eBooks · doi:10.1007/978-3-031-59475-5_7
Clinical Characteristics, Prognostic Factors and Therapeutic Strategies in Gastric Cancer Patients With Bone Metastasis: A Retrospective Analysis
Ren, S., Wei, Y., Liu, W., Zhang, Y., Wang, Y., Yang, J. D., Liu, B., Shi, T., & Wei, J. (2025) · Cancer Medicine · doi:10.1002/cam4.70781
Characterization and clinical implications of myeloid-derived suppressor cells in head and neck cancer
Chikamatsu, K. (2012) · 耳鼻咽喉科免疫アレルギー · doi:10.5648/jjiao.30.271
ChemoImmunoModulation: Focus on Myeloid Regulatory Cells
Shurin, M. R., & Umansky, V. (2013) · Springer eBooks · doi:10.1007/978-94-007-6217-6_26
Targeting of Suppressive Myeloid Cells via Small Molecule Immunomodulators
Kischuk, E. M. (2019) · Purdue e-Pubs (Purdue University System) · doi:10.25394/pgs.9778562
Additional file 1 of Drug-loaded microbubble delivery system to enhance PD-L1 blockade immunotherapy with remodeling immune microenvironment
Zheng, J., Huang, J., Zhang, L., Wang, M., Xu, L., Dou, X., Leng, X., Fang, M., Sun, Y., & Wang, Z. (2023) · Figshare · doi:10.6084/m9.figshare.22603513
Additional file 1 of Docetaxel-loaded M1 macrophage-derived exosomes for a safe and efficient chemoimmunotherapy of breast cancer
Zhao, Y., Zheng, Y., Zhu, Y., Li, H., Zhu, H., & Liu, T. (2022) · Figshare · doi:10.6084/m9.figshare.20423968
A Tumor Acidity‐Driven Transformable Nanomaterial Mediated Activation of Antigen‐Presenting Cells for Cancer Photoimmunotherapy
Wang, J., Zhang, Y., Li, B., Jing, H., & Yang, X. L. (2026) · Small Methods · doi:10.1002/smtd.202501713
Drug Delivery Systems for Resiquimod to Control Myeloid‐Derived Suppressor Cells in Cancer Immunotherapy
He, Y., & Yeo, Y. (2026) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70052
Aspects fonctionnels et pronostiques des cellules myéloïdes suppressives et de Foxp3 dans le cancer
Ladoire, S. (2011) · theses.fr (ABES) · doi:10.70675/f95be627zd09cz4fd2za49fz6b11ffb7363d
Inhibition of Transcription by Dactinomycin Reveals a New Characteristic of Immunogenic Cell Stress
Humeau, J. (2019) · theses.fr (ABES) · doi:10.70675/e42505daza57fz459az9dc5z1ef744d25b38
L'action ambivalente de l'agent anti-cancéreux 5-Fluorouracile sur les cellules myéloïdes immunosuppressives sous contrôle de l'acide docosahexaénoïque : Rôle de l'inflammasome NLRP3 et de la voie JNK dans la sécrétion de l'IL-1beta
Dumont, A. (2018) · theses.fr (ABES) · doi:10.70675/01e0a564z8829z4bebz978bz17aa7a43cb26
De l’ifosfamide au géranyloxy-ifosfamide : pharmacomodulation pour cibler et moduler l’immunité
Delahousse, J. (2019) · theses.fr (ABES) · doi:10.70675/516a5d4ez81ccz485azbe9cze077be422c4a
Role of Tissue-Resident Memory T (TRM) Cells in CD8+ T Cell Immunity and Response to Anti-PD-1 Immunotherapy : Involvement of TGF-β and αV Integrins
Malenica, I. (2019) · theses.fr (ABES) · doi:10.70675/410eb99fz6cbdz4f96z81bbze31bdbd1fabc
Cancer immunotherapy : efficacy and safety of a melanin-based vaccine
Cuzzubbo, S. (2021) · theses.fr (ABES) · doi:10.70675/2e1d38a6z8d99z458dza769zb7bccda2b709
Implication des monocytes-macrophages dans le développement de l'inflammation colique et de la carcinose péritonéale d'origine colorectale : rôle des récepteurs lectine de type-c et des récepteurs nucléaires PPARy et LRH-1
Jacquemin, G. (2021) · theses.fr (ABES) · doi:10.70675/eb1fecbaz8065z42ebzb918ze92070a1ff72
Chemotherapeutics as Immune Modulators for the Treatment of Triple-Negative Breast Cancer
Fines, C. B., Kelly, S., McCarthy, H. O., & Buckley, N. E. (2026) · Cancers · doi:10.3390/cancers18101537
Response to nivolumab as an immune checkpoint inhibitor rechallenge for esophageal squamous cell carcinoma with PD-L1 amplification: a case report
Kodama, H., Masuishi, T., Ishizuka, Y., Sakakida, T., Honda, K., Narita, Y., Taniguchi, H., Kadowaki, S., Ando, M., Hosoda, W., et al. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261451859
Overcoming Immune Suppression: Therapeutic Strategies Targeting T-Cell Function in Cancer
Weber, J. S. (2014) · Springer eBooks · doi:10.1007/978-1-4899-8056-4_16

Authors: Kodumudi, K. N., Woan, K., Gilvary, D. L., Sahakian, E., Wei, S., & Djeu, J. Y.
Affiliations: Moffitt Cancer Center (US)
Authors' Affiliation: Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida
Corresponding author: Djeu, Julie Y.
ORCID: Kodumudi, Krithika N.
Woan, Karrune
Sahakian, Eva
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2010-09-14
Volume: 16
Issue: 18
Pages: 4583-4594
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-10-0733
PMC: PMC3874864
OpenAlex: W2143994426
Cited by: 500
References: 42
Citations by year: 2026: 6 · 2025: 14 · 2024: 33 · 2023: 32 · 2022: 37 · 2021: 39 · 2020: 39 · 2019: 43 · 2018: 33 · 2017: 38 · 2016: 42 · 2015: 32 · 2014: 31 · 2013: 36 · 2012: 22
FWCI: 10.74
Type: journal article
Language: en
Open access: green
europepmc.org
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (T32CA115308)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: docetaxel, myeloid-derived suppressor cells, tumor immunosuppression, CTL response, CD4+ T cell activation, CD206, CCR7, macrophage differentiation, STAT3 signaling, tumor-bearing mice
MeSH terms: Docetaxel, Animals, Antineoplastic Agents, Cell Differentiation, Cytotoxicity, Immunologic, Female, Immune Tolerance, Immunosuppressive Agents, Lymphocyte Activation, Mice, Inbred BALB C, Mice, Transgenic, Neoplasm Transplantation, Neoplasms, T-Lymphocytes, Myeloid Cells, Taxoids, Cell Line, Tumor, Mice, Immunomodulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks